AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2024
Jan 4, 2024
32883_dirs_2024-01-03_3228a1ad-2bdc-4ff1-a081-b17d987a632e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-01-01
Reporting Person: RIOUX PATRICE (Acting Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | Stock Options | $0.3402 | A | 10000 | Acquired | 2033-12-31 | Common Stock (10000) | Direct |
Footnotes
F1: Stock Options vesting commenced on January 1, 2024 as follows: 833 on January 31, 2024 and each subsequent month-end thereafter.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Report Publication Announcement
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2